-
121
Image_1_Endothelial Cells Promote Docetaxel Resistance of Prostate Cancer Cells by Inducing ERG Expression and Activating Akt/mTOR Signaling Pathway.tif
منشور في 2020"…<p>Docetaxel is a first-line chemotherapy for the treatment of patients with castration-resistant prostate cancer (CRPC). …"
-
122
Image_3_Endothelial Cells Promote Docetaxel Resistance of Prostate Cancer Cells by Inducing ERG Expression and Activating Akt/mTOR Signaling Pathway.tif
منشور في 2020"…<p>Docetaxel is a first-line chemotherapy for the treatment of patients with castration-resistant prostate cancer (CRPC). …"
-
123
Image_2_Endothelial Cells Promote Docetaxel Resistance of Prostate Cancer Cells by Inducing ERG Expression and Activating Akt/mTOR Signaling Pathway.tif
منشور في 2020"…<p>Docetaxel is a first-line chemotherapy for the treatment of patients with castration-resistant prostate cancer (CRPC). …"
-
124
CDK4/6 inhibition presents as a therapeutic option for pediatric and adult germ cell tumors and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms
منشور في 2020"…Although high cure rates at early stages can be achieved, metastases, resistance to cisplatin-based therapy, and late toxicities still represent a lethal threat, arguing for the need of new therapeutic options. …"
-
125
-
126
-
127
-
128
DataSheet_6_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd...
منشور في 2021"…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…"
-
129
DataSheet_7_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd...
منشور في 2021"…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…"
-
130
DataSheet_2_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd...
منشور في 2021"…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…"
-
131
DataSheet_9_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.do...
منشور في 2021"…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…"
-
132
DataSheet_5_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd...
منشور في 2021"…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…"
-
133
DataSheet_1_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd...
منشور في 2021"…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…"
-
134
DataSheet_8_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd...
منشور في 2021"…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…"
-
135
DataSheet_4_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd...
منشور في 2021"…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…"
-
136
DataSheet_3_Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.pd...
منشور في 2021"…These findings were not more pronounced in patients with an alkaline phosphatase response during therapy.</p>Conclusion<p>Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.…"
-
137
Table_1_Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib.docx
منشور في 2020"…In the present study, we have investigated whether therapy with the novel HSP90 inhibitor onalespib can potentiate the efficacy of cisplatin and potentially reverse cisplatin resistance in ovarian and head and neck cancer cells.…"
-
138
Image_1_Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib.TIFF
منشور في 2020"…In the present study, we have investigated whether therapy with the novel HSP90 inhibitor onalespib can potentiate the efficacy of cisplatin and potentially reverse cisplatin resistance in ovarian and head and neck cancer cells.…"
-
139
Image_2_Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90 Inhibitor Onalespib.TIFF
منشور في 2020"…In the present study, we have investigated whether therapy with the novel HSP90 inhibitor onalespib can potentiate the efficacy of cisplatin and potentially reverse cisplatin resistance in ovarian and head and neck cancer cells.…"
-
140